Durvalumab Market
Report ID: SQMIG35I3410
Report ID: SQMIG35I3410
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3410 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
177
|Figures:
79
Global Durvalumab Market size was valued at USD 1.5 Billion in 2024 and is poised to grow from USD 1.64 Billion in 2025 to USD 3.29 Billion by 2033, growing at a CAGR of 9.1% during the forecast period (2026-2033).
Durvalumab, a human IgG1 monoclonal antibody targeting PD‑L1, underpins the rapidly expanding immuno‑oncology segment. The market revolves around its approval for unresectable stage III non‑small cell lung cancer (NSCLC) in 2017, followed by indications in extensive‑stage small‑cell lung cancer and urothelial carcinoma. These clearances generated a surge in physician adoption because the drug demonstrated prolonged overall survival compared with conventional chemoradiotherapy. Early uptake was reinforced by AstraZeneca’s partnership with Genentech, which broadened distribution across North America and Europe. Consequently, the market today encompasses a value chain of manufacturers, payers, and oncology centers, reflecting its clinical relevance and financial significance, recognition.
The principal growth catalyst for the Durvalumab market is its expanding indication portfolio, which leverages checkpoint blockade to improve outcomes across tumor types. The landmark PACIFIC trial demonstrated a five‑year overall survival benefit in stage III NSCLC, leading regulators to grant accelerated pathways and insurers to add the drug to reimbursement lists. This momentum fuels ongoing Phase III studies in head‑neck, colorectal and ovarian cancers, where early data show additive efficacy with radiation or chemotherapy. Real‑world adoption in academic centers reports fewer hospitalizations and lower immune‑related adverse events, attracting venture capital and prompting biosimilar development, thus driving further significant market expansion.
How is AI-Driven Biomarker Discovery Influencing the Durvalumab Market?
The advancement of biomarker discovery using AI is transforming the Durvalumab market as it allows for exact identification of tumor signatures that indicate the possible response. Scientists apply machine learning on genomic and clinical datasets to identify patients who are most likely to benefit from the treatment, minimizing the time needed to enroll patients for trial and improving the outcome data. This scientific clarity gives clinicians confidence to prescribe Durvalumab earlier in treatment pathways and encourages payers to support its use. The approach also fuels partnership interest as biotech firms seek to embed AI tools into their development pipelines. As a result the market is seeing a shift toward personalized regimens that align with Durvalumab’s immune checkpoint mechanism, creating a more sustainable growth trajectory.
In July 2025 , AstraZeneca announced priority review and breakthrough therapy designation for Durvalumab in early stage gastric and gastroesophageal junction cancers, a move driven by AI driven biomarker discovery that refines patient selection and supports market expansion. The approval pathway accelerates clinical uptake and demonstrates how data driven insights are translating into tangible commercial momentum.
Market snapshot - (2026-2033)
Global Market Size
USD 1.5 Billion
Largest Segment
Non-Small Cell Lung Cancer
Fastest Growth
Hepatocellular Carcinoma
Growth Rate
9.1% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global durvalumab market is segmented by indication, therapy type, distribution channel, end user, product type, route of administration and region. Based on indication, the market is segmented into non-small cell lung cancer, small cell lung cancer, biliary tract cancer, hepatocellular carcinoma and others. Based on therapy type, the market is segmented into monotherapy, combination with chemotherapy, combination with immunotherapy and others. Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, oncology pharmacies and others. Based on end user, the market is segmented into hospitals, cancer centers, specialty clinics and others. Based on product type, the market is segmented into branded, biosimilar and others. Based on route of administration, the market is segmented into intravenous infusion, hospital administration, ambulatory infusion centers and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Non small cell lung cancer segment dominates because it is the principal approved indication for durvalumab, generating the bulk of prescribing activity. Physicians focus on it due to extensive clinical evidence demonstrating survival improvement, and reimbursement frameworks are tightly aligned with this indication, creating a steady and sizable demand pipeline that sustains market momentum.
However, hepatocellular carcinoma segment emerges as the most rapidly expanding area, driven by recent trial data showing meaningful response rates in patients with limited treatment options. An increase in confidence from clinicians, a rise in trial enrollments, and changes in the acknowledgment of regulatory approvals have been facilitating the speedy adoption and opening new opportunities for growth and diversification in the market.
Combination with chemotherapy segment leads because it capitalizes on synergistic efficacy, widening the eligible patient base beyond monotherapy use. The incorporation of durvalumab into standard chemotherapy regimens allows oncologists to easily include it in treatment schemes they are already familiar with, thus motivating an extensive use of this method and strengthening the acceptance of this treatment course by payers.eamlessly within familiar treatment pathways, encouraging broader utilization and reinforcing payer support for the combined approach.
Meanwhile, combination with immunotherapy emerges as the most rapidly expanding area, propelled by emerging evidence of enhanced antitumor activity through dual checkpoint blockade. Ongoing clinical programs are expanding its therapeutic scope, attracting investigator interest and fostering early adoption, which together amplify market expansion and create fresh commercial opportunities.
To get detailed segments analysis, Request a Free Sample Report
North America holds a pre‑eminent position in the market in because it combines a mature oncology ecosystem with strong payer frameworks that support rapid uptake of innovative immunotherapies. The United States benefits from a highly integrated network of academic medical centers, leading clinical‑trial sites, and a regulatory pathway that encourages accelerated approval of breakthrough treatments. Canada's healthcare system is funded by the government and relies on evidence to decide on compensation which creates steady demand for drugs across Canadian provinces’ drug formularies. The combination of these factors ensures a positive environment for new checkpoint inhibitors to enter the market, thereby enabling manufacturers to operate smoothly and maintaining a solid background of practical experience that helps physicians to gain confidence. The focus on personalized medicine in the region serves to further enhance its appeal and make North America the unquestionable market leader for durvalumab.
Durvalumab market in the United States is propelled by extensive oncology networks that rapidly adopt checkpoint inhibitors, supported by sophisticated payer contracts that reimburse high‑cost therapies. Major cancer treatment centers are responsible for a lot of clinical trial work, thereby producing a cycle of information that confirms the effectiveness of such procedures and helping to formulate the rules of the treatment. In addition to that, the partnership between biotech companies and clinics helps to speed up the introduction of pharmaceutical products, while the support of patients' advocacy organizations encourages the use of the latest immunotherapy treatments.
Durvalumab market in Canada benefits from a universal health‑care framework that prioritizes cost‑effectiveness and clinical value, resulting in systematic assessment of new therapies. Provincial health authorities coordinate formulary decisions, ensuring consistent access across regions. Partnerships between academic institutions and industry research result in the generation of early evidence; on the other hand, oncology associations drive the implementation of guidelines. This cooperation lays down a good foundation for regular adoption of durvalumab in Canada, thus playing a key role in the North American market.
Europe experiences rapid expansion of the industry due to a harmonized regulatory environment that encourages swift approval of innovative oncology medicines across member states. The utilization of centralized health technology assessment mechanisms along with progressive reimbursement policies can be very fruitful in making it easier for the product to be adopted by the health systems of many countries. At the same time, the focus of the region on personalized cancer treatment encourages the doctors to use checkpoint inhibitors, as well as the collaborative studies conducted in the area. The respective partnership between the private and public sectors supports local production and the stability of supply, increasing confidence in the market. All these factors contribute to the faster introduction of durvalumab in the European health systems.
Durvalumab market in Germany dominates the European landscape, anchored by a comprehensive cancer‑care infrastructure that integrates cutting‑edge research with routine clinical practice. Robust health‑technology assessment mechanisms ensure timely reimbursement, while leading oncology centers drive early adoption through extensive trial participation. The country’s commitment to precision medicine encourages guideline updates that incorporate checkpoint inhibitors, and strong pharmaceutical presence supports consistent supply. These factors collectively sustain Germany’s leading role in the regional durvalumab ecosystem.
Durvalumab market in United Kingdom is the fastest growing in Europe, propelled by an agile NHS procurement model that emphasizes rapid access to breakthrough therapies. National policies on cancer give priority to immunotherapy resulting in the rapid appearance of Durvalumab in the treatment guidelines. Research hospitals and academic institutions provide high-quality data to make sure that the recommendations are adopted quickly. At the same time, joint projects of biotech companies and NHS trusts facilitate commercial distribution processes promoting the quick initiation of treatment in various countries across the UK.
Durvalumab market in France is emerging as a notable contributor, supported by a national health‑care system that balances cost containment with innovation adoption. French oncology societies actively promote immunotherapy integration, and regulatory agencies provide streamlined approval pathways for advanced therapies. Clinical research studies conducted at renowned academic institutions produce regional efficacy data, which in turn increases physicians’ confidence. The dynamic process facilitates the wider application of durvalumab, making France an important market for growth in Europe.
Asia Pacific is strengthening its position in the industry through a convergence of rising cancer incidence, expanding biotech capabilities, and proactive regulatory frameworks that facilitate timely access to novel immunotherapies. Countries like Japan and South Korea make large investments in translational research, which connects academic findings with commercial development. National health insurance systems increasingly value checkpoint inhibitors, which leads to the expansion of reimbursement coverage. Regional collaboration and coordinated clinical trials speed up data creation and government funding helps with the strengthening of domestic production. The initiatives help to strengthen patients’ access to medicines and make Durvalumab the necessary part of new cancer treatment systems in Asia Pacific.
Durvalumab market in Japan leverages a mature oncology ecosystem characterized by advanced diagnostic infrastructure and a strong emphasis on precision medicine. The national government has established fast-track programs for some novel approaches to treating cancer, as a result ensuring swift access to the market. Top hospitals in the country keep using Durvalumab as a part of the treatment methods, making sure high participation in clinical research produces evidence of effectiveness valid in the area. National health insurance creates full coverage of expenses for patients, while cooperation with local producers supports stable supplies of needed products. This is what makes Japan a key market for durvalumab in the region.
Durvalumab market in South Korea benefits from a dynamic health‑care system that prioritizes rapid adoption of innovative therapies. High-impact oncology drugs make them eligible for accelerated approvals from regulatory agencies whereas national insurance programs make reimbursement available. Major academic hospitals foster early adoption of Durvalumab by actively participating in clinical studies and developing treatment guidelines. Close cooperation among biotechnology companies and state bodies provides for effective home production and distribution making Korea a major player in the Asia-Pacific market of durvalumab.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Expanding Indication Landscape
The clinical success of durvalumab in multiple tumor types encourages pharmaceutical companies to pursue additional label extensions, thereby expanding the indication landscape. As oncologists gain confidence in its safety profile, they are more likely to incorporate the therapy into diverse treatment regimens, fostering broader patient eligibility. This expansion stimulates demand across hospitals and specialty clinics, creating a virtuous cycle of increased prescription volumes and heightened awareness among healthcare providers, ultimately driving sustained market growth. Such momentum also attracts investment in research and development, further reinforcing market expansion.
Advancements in Combination Therapies
Emerging evidence demonstrates that durvalumab synergizes effectively with chemotherapy, targeted agents, and radiation, prompting clinicians to adopt combination regimens that enhance therapeutic outcomes. By integrating durvalumab into multimodal treatment strategies, physicians can address heterogeneous tumor biology and improve response durability. This clinical advantage encourages healthcare institutions to allocate resources toward acquiring the drug and training staff, thereby elevating its market penetration. The broader acceptance of combination protocols also stimulates collaborative research initiatives, reinforcing product visibility and fostering continued expansion of the market.
High Treatment Cost Concerns
Durvalumab’s premium pricing presents a significant financial barrier for healthcare systems and patients, particularly in regions with limited reimbursement frameworks. When payers evaluate cost‑effectiveness, they may prioritize lower‑cost alternatives or delay adoption pending further economic assessments. This hesitation restricts formulary inclusion and reduces prescribing frequency, thereby curbing market expansion. Additionally, high out‑of‑pocket expenses can lead to patient non‑adherence, further diminishing demand and slowing the overall growth trajectory of the durvalumab market. Consequently, budget‑constrained institutions may allocate resources toward generic immunotherapies, further limiting durvalumab’s market share.
Regulatory Approval Uncertainties
The complex and evolving regulatory landscape for immune checkpoint inhibitors introduces uncertainty regarding timely approvals for new durvalumab indications. Agencies may require extensive clinical data to address safety concerns, leading to prolonged review periods and potential post‑marketing restrictions. Such delays hinder manufacturers’ ability to launch products promptly, affecting revenue streams and discouraging investment in further development. Moreover, divergent regional requirements create additional challenges for global commercialization, limiting the speed at which durvalumab can penetrate emerging markets and thereby restraining overall market growth.
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape in the global durvalumab market is shaped by AstraZeneca’s Imfinzi gaining FDA approvals for new combination regimens, prompting rivals to accelerate their own PD‑L1 pipelines and seek partnership deals that broaden indications. Recent collaborations between AstraZeneca and BCG manufacturers illustrate a strategy to lock in market share, while competitors such as Bristol‑Myers Squibb and GSK are pursuing M&A and co‑development agreements to expand their immuno‑oncology portfolios and counteract Imfinzi’s growing foothold.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis the global durvalumab industry is propelled primarily by an expanding indication landscape that adds new tumor types and widens patient eligibility, while high treatment cost concerns act as a significant restraint limiting adoption in budget‑constrained settings. North America remains the dominant region thanks to its mature oncology ecosystem and strong payer support, and the non‑small cell lung cancer indication continues to drive the largest share of sales. A second important driver is AI‑enabled biomarker discovery, which sharpens patient selection, accelerates trial enrollment and builds payer confidence, further reinforcing market growth. These dynamics together forecast a robust compound annual growth rate of roughly nine percent through 2033.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 1.5 Billion |
| Market size value in 2033 | USD 3.29 Billion |
| Growth Rate | 9.1% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Durvalumab Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Durvalumab Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Durvalumab Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Durvalumab Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Durvalumab Market size was valued at USD 1.5 Billion in 2024 and is poised to grow from USD 1.64 Billion in 2025 to USD 3.29 Billion by 2033, growing at a CAGR of 9.1% during the forecast period (2026-2033).
The competitive landscape is shaped by AstraZeneca’s Imfinzi gaining FDA approvals for new combination regimens, prompting rivals to accelerate their own PD‑L1 pipelines and seek partnership deals that broaden indications; recent collaborations between AstraZeneca and BCG manufacturers illustrate a strategy to lock in market share, while competitors such as Bristol‑Myers Squibb and GSK are pursuing M&A and co‑development agreements to expand their immuno‑oncology portfolios and counteract Imfinzi’s growing foothold. 'AstraZeneca plc', 'Merck & Co., Inc.', 'Bristol Myers Squibb Company', 'F. Hoffmann-La Roche Ltd.', 'Pfizer Inc.', 'Novartis AG', 'Johnson & Johnson', 'Sanofi S.A.', 'Eli Lilly and Company', 'BeiGene, Ltd.', 'Regeneron Pharmaceuticals, Inc.', 'Genmab A/S', 'Incyte Corporation', 'Exelixis, Inc.', 'Arcus Biosciences, Inc.', 'Coherus BioSciences, Inc.', 'Cullinan Therapeutics, Inc.', 'MacroGenics, Inc.', 'Immutep Limited', 'Compugen Ltd.'
Combination Therapy Expansion: Oncologists are increasingly pairing durvalumab with other checkpoint inhibitors, targeted agents, and chemotherapy regimens to enhance anti‑tumor activity. Clinical collaborations across academic and commercial sectors are generating robust data that demonstrate synergistic effects and improved patient outcomes. This therapeutic convergence is prompting healthcare providers to adopt multimodal treatment protocols, thereby broadening durvalumab’s clinical applicability beyond its initial indications and driving greater market penetration across diverse oncology settings, and supporting long‑term therapeutic strategies that align with emerging personalized medicine frameworks for patient cohorts.
Why does North America Dominate the Global Durvalumab Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
